Coronary Reactivity Assessment Linked to Lower Healthcare Costs in ANOCA Patients

Many people with chest pain leave the hospital after an angiogram only to hear that their major coronary arteries look clear, even as their angina pain persists. This frustrating scenario, known as angina with nonobstructive coronary arteries (ANOCA) or ischemia with no obstructive coronary disease (INOCA), is more common than many realize. In fact, studies show that up to half of all patients (and an even higher share of women) who get a coronary angiogram for chest pain end up with “normal” results. This situation leaves patients without answers. Now, new research suggests there may be a better way forward. By performing specialized coronary reactivity testing which measures how the small blood vessels and the lining of the heart’s arteries respond doctors can uncover hidden problems that ordinary imaging misses. Early evidence shows that when patients with ANOCA get this extra testing, doctors can tailor treatments more precisely. In fact, one recent study linked coronary reactivity assessment with lower overall healthcare costs for these patients.

Why It Matters

The individual that suffers from chest pain without blocked arteries finds himself or herself in a sort of limbo in medicine. The lack of a concrete cause causes frustration not only for patients but also for doctors who have to deal with their complaints. People can suffer from angina attacks while angiograms reveal no abnormalities in their large arteries. The situation often makes patients feel ignored or undervalued. Doctors find themselves forced to conduct several additional tests or prescribe medications based on trial and error. This added expense and stress impacts everyone involved. Not knowing the source of the problem means the patient will see more physicians and undergo additional tests, even those involving invasions which likely will not do anything for them. All these extra visits translate into expenses. This also takes an immense toll psychologically, since symptoms like chest pain without knowing why it is there causes stress and loss of workdays, along with additional economic pressure in terms of co-pays and lost wages. Health systems also suffer as the extra diagnostic work and unnecessary admissions take resources away from other patients who need them. Microvascular angina is now being taken seriously by major cardiovascular organizations.

Who It Affects

This problem starts with the patients. People who have chronic chest pain but show “normal” angiograms often feel anxious and helpless. Many are middle-aged or older, and a large share are women – although anyone can have it. These patients may have a lower quality of life. They might make repeated trips to the ER for chest pain or be told their symptoms are “all in their head,” which leaves them still suffering and feeling dismissed.

Doctors and healthcare teams feel it too. Without clear findings on a standard angiogram, cardiologists and general doctors face a tough choice. They might try different medications one at a time or order more tests, hoping to find an answer. A coronary reactivity assessment gives them a helpful next step by checking small-vessel health. But this needs special training and extra procedure time, which not every cath lab team is ready for.

Hospitals and insurance companies have skin in the game as well. Repeated ER visits, extra scans, and specialist consultations for ANOCA patients add up in cost. If one thorough test can prevent multiple later visits, the health system could save money. Still, not every hospital can do this testing yet. Larger medical centers often have the equipment and trained staff, while smaller or rural hospitals may not. Insurance coverage is also key – if insurers don’t pay for the test or follow-up care, many patients simply cannot get it.

What Changes

• Clearer diagnoses for patients. Instead of shrugging and saying “we don’t know,” a reactivity test can show whether the problem is in the small vessels or the artery lining. This gives patients a real diagnosis to work with and changes the treatment plan.
• Fewer unnecessary tests and visits. When doctors understand the cause of symptoms, they avoid broad, repeated scans and ER trips. That reduces cost and frustration for everyone.
• More targeted treatments. If the test shows microvascular dysfunction or artery spasms, doctors can prescribe therapies known to work for those problems. This helps patients faster and avoids one-size-fits-all trial-and-error with medications.
• System and staffing changes. To do these tests routinely, hospitals need trained cath lab teams, a little extra procedure time, and smooth care pathways. Insurance and reimbursement policies also have to cover both the testing and the follow-up care it leads to.
• Empowered patients. When patients understand the cause of their chest pain, they feel heard and are more engaged in their care. This can improve satisfaction and their commitment to following treatment plans.
• Stronger collaboration. Introducing this testing encourages teamwork among cardiologists, primary care doctors, and other clinicians, leading to a more unified and effective care plan for patients.

Implementation and Access: Doing coronary reactivity tests means a patient must be sent to a catheterization lab and an angiogram must include extra measurements. This adds procedure time and a little risk (though any invasive test has some chance of complication). It also requires special equipment and training. Not every hospital can do this. Large heart centers usually have the right tools and experience, but smaller or rural hospitals may not. For example, doctors may inject a special drug during the test to see if an artery spasms or to measure how well blood flows through small vessels. These extra checks add only a few minutes to the procedure but can reveal important issues. Insurance coverage also matters – if insurers don’t reimburse the test or the follow-up treatments, many doctors won’t offer it. This could also create disparities: if only certain hospitals can offer the test, patients in underserved areas might miss out. Addressing equity in access is therefore an important part of the conversation.

Ongoing Care and Clinician View: A positive test result isn’t a quick fix, but it gives direction. Finding microvascular dysfunction or spasms means doctors can choose medications and therapies tailored to those problems. Still, many patients will need ongoing support over time. The best results come from clinics that combine cardiology care with rehab and counseling, helping patients manage their symptoms. For example, programs that include guided exercise or stress management can help improve blood flow and reduce symptoms over time. For doctors, having this test means less guesswork. Instead of prescribing medications one by one hoping one works, they can match treatment to a real diagnosis. Patients often get relief faster and avoid side effects from ineffective drugs. This targeted approach improves quality of life and cuts waste in the system. It can also boost patient trust – seeing a doctor take concrete action helps them feel more confident in their care plan.

Evidence, Policy, and Next Steps: So far, studies linking coronary reactivity tests to lower costs are observational. They suggest patients tend to use fewer healthcare resources after a test, but that doesn’t prove the test itself caused the savings. The cost benefits only appear when doctors act on the results and provide the right treatment. Without follow-up care, the potential savings disappear. To make this strategy work broadly, health systems need clear pathways. Guidelines should identify which patients are candidates for testing, and insurance should cover both the test and the treatments that follow. Training more cardiologists and cath lab teams will lower the barrier to using these tests. Policymakers and hospital leaders should note that investing in better diagnostics can pay off, but only if the whole care plan – from testing to treatment to follow-up – is in place.

Finally, the message for patients is simple: if you have ongoing angina pain but a “normal” angiogram, don’t settle for uncertainty. Ask your cardiologist if a coronary reactivity test could be helpful. It might pinpoint what’s causing your symptoms and open the door to treatments that really make you feel better.

Coronary reactivity assessment is not a cure-all for every patient, but it can be a key part of a complete care plan. By confirming a diagnosis and guiding treatment, it helps patients feel heard and treated correctly. It also prevents waste: fewer unnecessary tests and better-targeted therapies mean lower costs and better health outcomes. The real payoff comes when healthcare teams use this tool and then fully follow through – giving patients the care they need and avoiding guesswork in care decisions. For patients, getting a clear diagnosis often means they feel heard and can participate more fully in their treatment, improving satisfaction and outcomes. This benefits everyone – it saves money for the health system and gives patients hope for better health. In the end, replacing uncertainty with a clear diagnosis is a win for everyone. Overall, this is a promising approach that deserves broader attention in cardiovascular care.

References

1. Maayah M, Latif N, Vijay A, Gallegos CM, Cigarroa N, Posada Martinez EL, et al. Evaluating ischemic heart disease in women: focus on angina with nonobstructive coronary arteries (ANOCA). Journal of the Society for Cardiovascular Angiography & Interventions. 2024;3(8):102195. Available from: PubMed Central full text [\[pmc.ncbi.nlm.nih.gov\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC11330936/)
2. Ford TJ, Stanley B, Sidik N, Good R, Rocchiccioli P, McEntegart M, et al. 1-Year outcomes of angina management guided by invasive coronary function testing (CorMicA). JACC: Cardiovascular Interventions. 2020;13(1):33-45. Available from: PubMed Central full text [\[pmc.ncbi.nlm.nih.gov\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8310942/)
3. Ahmad A, Corban MT, Moriarty JP, Kanaji Y, Rosedahl JK, Gulati R, et al. Coronary reactivity assessment is associated with lower health care-associated costs in patients presenting with angina and nonobstructive coronary artery disease. Circulation: Cardiovascular Interventions. 2023;16:e012387. Available from: American Heart Association article PDF [\[ahajournals.org\]](https://www.ahajournals.org/doi/pdf/10.1161/CIRCINTERVENTIONS.122.012387)
4. Berry C, Camici PG, Crea F, et al.; on behalf of the Coronary Vasomotor Disorders International Study (COVADIS) Group. Clinical standards in angina and non-obstructive coronary arteries: a clinician and patient consensus statement. International Journal of Cardiology. 2025;429:133162. Available from: Full text [\[internatio…iology.com\]](https://www.internationaljournalofcardiology.com/article/S0167-5273%2825%2900205-0/fulltext)